{"id":987512,"date":"2026-07-30T16:08:34","date_gmt":"2026-07-30T20:08:34","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/annexon-secures-strategic-credit-facility-for-up-to-200-million-from-oxford-finance\/"},"modified":"2026-07-30T16:08:34","modified_gmt":"2026-07-30T20:08:34","slug":"annexon-secures-strategic-credit-facility-for-up-to-200-million-from-oxford-finance","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/annexon-secures-strategic-credit-facility-for-up-to-200-million-from-oxford-finance\/","title":{"rendered":"Annexon Secures Strategic Credit Facility for up to $200 Million from Oxford Finance"},"content":{"rendered":"

\n Expands Financial Capacity as Vonaprument and Tanruprubart Programs Advance Toward Registration
\n<\/h2>\n
\n

BRISBANE, Calif., July 30, 2026 (GLOBE NEWSWIRE) — Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies for multiple neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that it has entered into a strategic credit facility agreement with Oxford Finance LLC (\u201cOxford Finance\u201d) for up to $200 million.<\/p>\n

\u201cThis strategic facility enhances our financial and operational capabilities as we prepare for the potential global commercialization of vonaprument and tanruprubart, which combined have the potential to reach millions of patients worldwide,\u201d said Douglas Love, president and chief executive officer of Annexon. \u201cAccess to this non-dilutive capital further diversifies our capital structure, strengthens our balance sheet, and accelerates our near and long-term growth strategy.\u201d<\/p>\n

Kirk Andrews, Managing Director of Oxford Finance added, \u201cAnnexon is advancing a differentiated approach to complement-driven neuroinflammatory disease with two programs approaching registration. We are pleased to provide a milestone-based financing facility that reflects our confidence in Annexon\u2019s strategy, execution, and ability to advance vonaprument and tanruprubart through key value-driving milestones in support of patients globally.\u201d<\/p>\n

Under the terms of the agreement, Annexon drew an initial $50 million at closing. An additional $100 million will become available upon the company\u2019s achievement of certain milestones related to its vonaprument and tanruprubart registrational programs, with the remaining $50 million available subject to lender approval.<\/p>\n

\n About Annexon<\/strong>
\n
Annexon Biosciences (Nasdaq: ANNX) is advancing the next generation platform of targeted immunotherapies for nearly 10 million people worldwide living with serious neuroinflammatory diseases. Our founding scientific approach focuses on C1q, the initiating molecule of a potent inflammatory pathway that when misdirected can lead to tissue damage and loss of function in a host of diseases. Our targeted therapies are designed to stop classical complement-driven neuroinflammation at its source to provide meaningful functional benefit and alter the course of disease. Annexon\u2019s mission is to deliver game-changing therapies to patients so that they can live their best lives. To learn more visit\u00a0annexonbio.com<\/a>.<\/p>\n

\n About Oxford Finance<\/strong>
\n
Oxford Finance LLC is a specialty finance firm providing senior secured loans to public and private companies operating in a variety of industries worldwide. For over 20 years, Oxford has delivered flexible financing solutions to over 750 companies, allowing borrowers to maximize their equity by leveraging their assets. Since 2002, Oxford has originated more than $18 billion in loans. Oxford is headquartered in Alexandria, Virginia, with additional offices serving the greater San Diego, San Francisco, Atlanta and New York City metropolitan areas. For more information, visit\u00a0www.oxfordfinance.com.<\/a><\/p>\n

\n Forward Looking Statements<\/strong>
\n
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, you can identify forward-looking statements by terminology such as \u201caim,\u201d \u201canticipate,\u201d \u201cassume,\u201d \u201cbelieve,\u201d \u201ccontemplate,\u201d \u201ccontinue,\u201d \u201ccould,\u201d \u201cdesign,\u201d \u201cdue,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cgoal,\u201d \u201cintend,\u201d \u201cmay,\u201d \u201cobjective,\u201d \u201cplan,\u201d \u201cpositioned,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cseek,\u201d \u201cshould,\u201d \u201ctarget,\u201d \u201cwill,\u201d \u201cwould\u201d and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. All statements other than statements of historical facts contained in this press release are forward-looking statements. These forward-looking statements include but are not limited to the potential for the company to draw up to an additional $150 million under the credit facility; and continuing advancement of the company\u2019s portfolio and the potential global commercialization of vonaprument and tanruprubart. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, risks and uncertainties related to: the company\u2019s history of net operating losses; the company\u2019s ability to obtain necessary capital to fund its clinical programs; the potential for delays in the company\u2019s clinical trials; the potential for the company\u2019s product candidates to not receive regulatory approval, including if the FDA and comparable foreign regulatory authorities determine that the company\u2019s submission package is not sufficient or require the company to provide additional data in patients that are not feasible to obtain; the early stages of clinical development of the company\u2019s product candidates; the effects of public health crises on the company\u2019s clinical programs and business operations; the company\u2019s ability to obtain regulatory approval of and successfully commercialize its product candidates; any undesirable side effects or other properties of the company\u2019s product candidates; the company\u2019s reliance on third-party suppliers and manufacturers; the outcomes of any future collaboration agreements; and the company\u2019s ability to adequately maintain intellectual property rights for its product candidates. These and other risks are described in greater detail under the section titled \u201cRisk Factors\u201d contained in the company\u2019s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q and the company\u2019s other filings with the Securities and Exchange Commission. Any forward-looking statements that the company makes in this press release are made pursuant to the Private Securities Litigation Reform Act of 1995, as amended, and speak only as of the date of this press release. Except as required by law, the company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.<\/p>\n

\n Investor Contact:<\/strong>
\n
Joyce Allaire
LifeSci Advisors
jallaire@lifesciadvisors.com<\/a><\/p>\n

\n Media Contact:<\/strong>
\n
Beth Keshishian
917-912-7195
beth@bethkeshishian.com<\/a><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

Expands Financial Capacity as Vonaprument and Tanruprubart Programs Advance Toward Registration BRISBANE, Calif., July 30, 2026 (GLOBE NEWSWIRE) — Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies for multiple neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that it has entered into a strategic credit facility agreement with Oxford Finance LLC (\u201cOxford Finance\u201d) for up to $200 million. \u201cThis strategic facility enhances our financial and operational capabilities as we prepare for the potential global commercialization of vonaprument and tanruprubart, which combined have the potential to reach millions of patients worldwide,\u201d said Douglas Love, president and chief executive officer of Annexon. \u201cAccess to this non-dilutive capital further diversifies our capital structure, … <\/p>\n

Continue reading “Annexon Secures Strategic Credit Facility for up to $200 Million from Oxford Finance”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-987512","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nAnnexon Secures Strategic Credit Facility for up to $200 Million from Oxford Finance - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/annexon-secures-strategic-credit-facility-for-up-to-200-million-from-oxford-finance\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Annexon Secures Strategic Credit Facility for up to $200 Million from Oxford Finance - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Expands Financial Capacity as Vonaprument and Tanruprubart Programs Advance Toward Registration BRISBANE, Calif., July 30, 2026 (GLOBE NEWSWIRE) — Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies for multiple neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that it has entered into a strategic credit facility agreement with Oxford Finance LLC (\u201cOxford Finance\u201d) for up to $200 million. \u201cThis strategic facility enhances our financial and operational capabilities as we prepare for the potential global commercialization of vonaprument and tanruprubart, which combined have the potential to reach millions of patients worldwide,\u201d said Douglas Love, president and chief executive officer of Annexon. \u201cAccess to this non-dilutive capital further diversifies our capital structure, … Continue reading "Annexon Secures Strategic Credit Facility for up to $200 Million from Oxford Finance"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/annexon-secures-strategic-credit-facility-for-up-to-200-million-from-oxford-finance\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-30T20:08:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgwMTIwOCM3NzUyMDM2IzIxOTAwOTI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annexon-secures-strategic-credit-facility-for-up-to-200-million-from-oxford-finance\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annexon-secures-strategic-credit-facility-for-up-to-200-million-from-oxford-finance\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Annexon Secures Strategic Credit Facility for up to $200 Million from Oxford Finance\",\"datePublished\":\"2026-07-30T20:08:34+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annexon-secures-strategic-credit-facility-for-up-to-200-million-from-oxford-finance\\\/\"},\"wordCount\":912,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annexon-secures-strategic-credit-facility-for-up-to-200-million-from-oxford-finance\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgwMTIwOCM3NzUyMDM2IzIxOTAwOTI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annexon-secures-strategic-credit-facility-for-up-to-200-million-from-oxford-finance\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annexon-secures-strategic-credit-facility-for-up-to-200-million-from-oxford-finance\\\/\",\"name\":\"Annexon Secures Strategic Credit Facility for up to $200 Million from Oxford Finance - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annexon-secures-strategic-credit-facility-for-up-to-200-million-from-oxford-finance\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annexon-secures-strategic-credit-facility-for-up-to-200-million-from-oxford-finance\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgwMTIwOCM3NzUyMDM2IzIxOTAwOTI=\",\"datePublished\":\"2026-07-30T20:08:34+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annexon-secures-strategic-credit-facility-for-up-to-200-million-from-oxford-finance\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annexon-secures-strategic-credit-facility-for-up-to-200-million-from-oxford-finance\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annexon-secures-strategic-credit-facility-for-up-to-200-million-from-oxford-finance\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgwMTIwOCM3NzUyMDM2IzIxOTAwOTI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgwMTIwOCM3NzUyMDM2IzIxOTAwOTI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annexon-secures-strategic-credit-facility-for-up-to-200-million-from-oxford-finance\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Annexon Secures Strategic Credit Facility for up to $200 Million from Oxford Finance\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Annexon Secures Strategic Credit Facility for up to $200 Million from Oxford Finance - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/annexon-secures-strategic-credit-facility-for-up-to-200-million-from-oxford-finance\/","og_locale":"en_US","og_type":"article","og_title":"Annexon Secures Strategic Credit Facility for up to $200 Million from Oxford Finance - Market Newsdesk","og_description":"Expands Financial Capacity as Vonaprument and Tanruprubart Programs Advance Toward Registration BRISBANE, Calif., July 30, 2026 (GLOBE NEWSWIRE) — Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies for multiple neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that it has entered into a strategic credit facility agreement with Oxford Finance LLC (\u201cOxford Finance\u201d) for up to $200 million. \u201cThis strategic facility enhances our financial and operational capabilities as we prepare for the potential global commercialization of vonaprument and tanruprubart, which combined have the potential to reach millions of patients worldwide,\u201d said Douglas Love, president and chief executive officer of Annexon. \u201cAccess to this non-dilutive capital further diversifies our capital structure, … Continue reading \"Annexon Secures Strategic Credit Facility for up to $200 Million from Oxford Finance\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/annexon-secures-strategic-credit-facility-for-up-to-200-million-from-oxford-finance\/","og_site_name":"Market Newsdesk","article_published_time":"2026-07-30T20:08:34+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgwMTIwOCM3NzUyMDM2IzIxOTAwOTI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/annexon-secures-strategic-credit-facility-for-up-to-200-million-from-oxford-finance\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/annexon-secures-strategic-credit-facility-for-up-to-200-million-from-oxford-finance\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Annexon Secures Strategic Credit Facility for up to $200 Million from Oxford Finance","datePublished":"2026-07-30T20:08:34+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/annexon-secures-strategic-credit-facility-for-up-to-200-million-from-oxford-finance\/"},"wordCount":912,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/annexon-secures-strategic-credit-facility-for-up-to-200-million-from-oxford-finance\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgwMTIwOCM3NzUyMDM2IzIxOTAwOTI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/annexon-secures-strategic-credit-facility-for-up-to-200-million-from-oxford-finance\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/annexon-secures-strategic-credit-facility-for-up-to-200-million-from-oxford-finance\/","name":"Annexon Secures Strategic Credit Facility for up to $200 Million from Oxford Finance - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/annexon-secures-strategic-credit-facility-for-up-to-200-million-from-oxford-finance\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/annexon-secures-strategic-credit-facility-for-up-to-200-million-from-oxford-finance\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgwMTIwOCM3NzUyMDM2IzIxOTAwOTI=","datePublished":"2026-07-30T20:08:34+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/annexon-secures-strategic-credit-facility-for-up-to-200-million-from-oxford-finance\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/annexon-secures-strategic-credit-facility-for-up-to-200-million-from-oxford-finance\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/annexon-secures-strategic-credit-facility-for-up-to-200-million-from-oxford-finance\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgwMTIwOCM3NzUyMDM2IzIxOTAwOTI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgwMTIwOCM3NzUyMDM2IzIxOTAwOTI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/annexon-secures-strategic-credit-facility-for-up-to-200-million-from-oxford-finance\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Annexon Secures Strategic Credit Facility for up to $200 Million from Oxford Finance"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/987512","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=987512"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/987512\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=987512"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=987512"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=987512"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}